Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$14.55 +4.46%

+$0.43 today

Market cap
$1.08B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 2.53M

Average 1.55M

OMER Net Income

Bottom-line profit after all expenses, interest, and taxes.

Omeros CorporationNASDAQ: OMER

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns positive

Q1 FY2026 net income was $56.06M, compared with -$33.46M a year earlier. Trailing-twelve-month net income was $86.17M.

Context

  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of $3.25M (+197.2%) for the fiscal year ending Dec 2026, a step up from the +97.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$56.06M-35.2% QoQ
Last fiscal yearDec 2025
-$3.35M+97.9% YoY
LTMMar 2026
$86.17M+156.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+267.5%+38.8%-228.7 pp
1 year+97.9%+197.2%+99.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(3.35M) USD
Year-over-year change
+97.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How OMER compares with its peers on the latest reported figures

  • OMER's LTM Mar 2026 net income of $86.17M is the highest of the 11 companies compared; the peer median is -$113.74M.
  • Its year-over-year change of +156.3% is the 2nd highest of 11, against a peer median of +1.0%.
  • Net income amounts to 871.0% of revenue for OMER, versus a peer median of 155.6%.
OMER Competitors Peer median
Net Income for OMER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OMEROmeros CorporationLTM Mar 2026$86.17M +156.3%—871.0%
CGENCompugen Ltd.LTM Mar 2026$34.86M +346.4%—48.0%
ANABAnaptysBio, Inc.LTM Mar 2026-$26.79M +81.0%—11.5%
MREOMereo BioPharma Group plcLTM Mar 2026-$35.7M +24.2%—7139.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$44.17M -6.7%——
MGNXMacroGenics, Inc.LTM Mar 2026-$70.36M -26.1%—44.8%
NKTRNektar TherapeuticsLTM Jun 2026-$157.13M -28.5%—287.8%
XNCRXencor, Inc.LTM Jun 2026-$163.33M +8.8%—155.6%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$221.04M -23.7%——
RCUSArcus Biosciences, Inc.LTM Jun 2026-$452M -47.7%—386.3%
BHVNBiohaven Ltd.LTM Jun 2026-$586.84M +23.5%——
Peer median (excluding OMER) -$113.74M+1.0%—155.6%

Competitors are the stored peer set for OMER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.39M0000
Gross Profit(1.39M)0000
Gross Margin—————
Research & Development118.78M112.72M114.87M119.52M81.3M
Selling, General & Admin53.46M50.67M49.66M49.74M41.5M
Operating Expenses172.23M163.39M164.53M169.26M122.8M
Depreciation & Amortization1.39M952K920K950K964K
EBITDA(170.49M)(158.38M)(143.16M)(157M)(1.83M)
EBITDA Margin—————
Operating Income(173.62M)(163.39M)(164.53M)(169.26M)(122.8M)
Operating Margin—————
Interest Income17.93K4.06M16.34M11.3M5.06M
Interest Expense19.67M22.7M30.84M24.68M0
Other Income / Expenses(17.93M)(18.64M)(10.39M)(13.37M)120M
Income Before Tax(191.55M)(182.03M)(174.92M)(182.63M)(2.8M)
Pre-Tax Margin—————
Income Tax Expense00002.01M
Net Income(111.41M)47.42M(117.81M)(156.82M)(3.35M)
Net Margin—————
EPS (Basic)3.120.46(1.88)(2.70)(0.05)
EPS (Diluted)3.120.46(1.88)(2.70)(0.05)
Weighted Avg Shares62.34M62.74M62.74M58.17M63.51M
Weighted Avg Shares (Diluted)62.34M62.74M62.74M58.17M63.51M

Omeros Corporation

NASDAQ:OMER

Intrinsic Alpha fair value

Locked

Current Price

$14.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.